G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 28.6 PLN 2.88% Market Closed
Market Cap: 37.8m PLN

Operating Margin
Genomed SA

13.4%
Current
5%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.4%
=
Operating Profit
3.7m
/
Revenue
27.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Genomed SA
WSE:GEN
37.8m PLN
13%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
No Stocks Found

Genomed SA
Glance View

Market Cap
37.8m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
38.88 PLN
Undervaluation 26%
Intrinsic Value
Price
G
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.4%
=
Operating Profit
3.7m
/
Revenue
27.5m
What is the Operating Margin of Genomed SA?

Based on Genomed SA's most recent financial statements, the company has Operating Margin of 13.4%.

Back to Top